Perry Robins, MD, is Professor Emeritus of Dermatology at the New York University School of Medicine. Dr. Robins has practiced medicine for over 40 years and has treated more than 47,000 skin cancer patients. Over 40% of the doctors who specialize in skin cancer were either trained by Dr. Robins himself or by doctors he has trained. He has lectured in 37 countries in 4 languages. At present, he performs more than 500 procedures annually and conducts training workshops for his peers on advanced techniques of dermatologic surgery. Dr. Robins is the founder and President of The Skin Cancer Foundation, a national organization dedicated to the research of skin cancer and public and medical education. Dr. Robins is also the founder/president of the International Society of Dermatologic Surgeons, founder/former-president of the Mohs Society, and former-president of the American Society of Dermatologic Surgery.

Board-certified dermatologist, Deborah S. Sarnoff MD, is one of the country's premier specialists in Mohs surgery for the treatment of skin cancer, cosmetic dermatology, and laser surgery. Dr. Sarnoff graduated from the George Washington University School of Medicine with distinction and received her residency and fellowship training in Mohs surgery and dermatologic surgery at New York University, under the direction of Dr. Perry Robins.Currently, Dr. Sarnoff is a Clinical Professor of Dermatology at NYU School of Medicine, President of The Skin Cancer Foundation, President of the International Society for Dermatologic Surgery and Secretary/Treasurer of The NYS Society of Dermatology and Dermatologic Surgery. Dr. Sarnoff is also Director of Dermatologic Surgery at Cosmetique Dermatology, Laser & Plastic Surgery, located in New York City.

Macrene Alexiades MD PhD Robert Baran MD Joseph B. Bikowski MD Dee Anna Glaser MD C. William Hanke MD William Levis MD Ronald L. Moy MD Keyvan Nouri MD Neil S. Sadick MD Gerhard Sattler MD James M. Spencer MD Susan H. Weinkle MD

Senior Associate Editors

Kenneth Beer MD Martin Braun MD Jeffrey Phillip Callen MD Jean Carruthers MD James Q. Del Rosso DO Lawrence F. Eichenfield MD Patricia Farris MD Norman Goldstein MD Aditya K. Gupta MD PhD Elizabeth Hale MD Sherry H. Hsiung MD Leon Kircik MD Mark Lebwohl MD Henry W. Lim MD Flor Mayoral MD Maurizio Podda MD PhD Jeffrey Orringer MD Maritza Perez MD Kevin Pinski MD Luigi Rusciani Scorza MD Ritu Saini MD Jerome l. Shupack MD Amy Taub MD Danny Vleggaar MD Brian Zelickson MD

Kendra G. Bergstrom MD Joel L. Cohen MD Adam Friedman MD James L. Griffith MD Marissa Heller MD Isaac Zilinsky MD

Past Co-Editors-In-Chief

Elizabeth Hale MD (2004) Susan H. Weinkle MD (2005-2008) Keyvan Nouri MD (2005-2008) Sherry H. Hsiung MD (2008) James M. Spencer MD (2009-2013)

About Us

The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology.

We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality.

Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.

JDD reaches around 13,760 dermatology healthcare professionals and has been recognized as the official partner of the Skin of Color Update (SOCU) and the ODAC Dermatology Aesthetic and Surgical (ODAC) conferences.

The extremely current and practical editorial content of JDD results in high readership and maximum exposure among the dermatology community.

Our Mission is Excellence through Peer Review: To educate physicians, optimize patient outcomes, and disseminate key scientific information.

JDD is published by SanovaWorks.

In the News

Journal of Drugs in Dermatology Publishes Study Showcasing Clinical Improvements with Burt’s Bees’ Sensitive Skin Regimen as Adjunct to Rosacea Prescription Therapy

DURHAM, N.C.–(BUSINESS WIRE)–Burt’s Bees, a leading provider of personal care products committed to natural health and beauty solutions, today announced that the Journal of Drugs in Dermatology has published clinical data supporting the efficacy and tolerability of Burt’s Bees skin care products as an adjunct to rosacea prescription therapy. Abs

Hormonal Therapies for Women with Acne

Hormonal therapies are helping to broaden therapeutic options for women with acne as dermatologists look for alternatives to antibiotic treatment. Studies suggest oral contraceptive pills and antiandrogen therapies might rival antibiotics in acne treatment efficacy…

Burt’s Bees Nature-Based Sensitive Skin Care Clinical Results Published in Journal of Drugs in Dermatology

DURHAM, N.C.–(BUSINESS WIRE)–Burt’s Bees^®, a leading provider of personal care products committed to natural health and beauty solutions, today announced that the Journal of Drugs in Dermatology (JDD) published clinical data supporting the efficacy of Burt’s Bees nature-based sensitive skin regimen at maintaining healthy skin barrier function.
Read More